Formosa Pharmaceuticals, Inc.

✨ Exciting news this Thanksgiving! Formosa Pharmaceuticals, Inc. is thrilled to announce the execution of a licensing agreement with Medvisis Switzerland for Clobetasol Propionate Ophthalmic Suspension, a treatment for post-operative inflammation and pain. This partnership marks a significant step in bringing this innovative solution to the Swiss market. 🏔️ We are grateful for the trust and collaboration that make this milestone possible. Happy Thanksgiving to all! 🦃 https://shorturl.at/b7KY7 https://shorturl.at/PMpOg #ClobetasolBID #APP13007 #SWISS #OcularSurgery

✨ Exciting news this Thanksgiving! Formosa Pharmaceuticals, Inc. is thrilled to announce the execution of a licensing agreement with Medvisis Switzerland for Clobetasol Propionate Ophthalmic Suspension, a treatment for post-operative inflammation and pain. This partnership marks a significant step in bringing this innovative solution to the Swiss market. 🏔️ We are grateful for the trust and collaboration that make this milestone possible. Happy Thanksgiving to all! 🦃 https://shorturl.at/b7KY7 https://shorturl.at/PMpOg #ClobetasolBID #APP13007 #SWISS #OcularSurgery

🔅 We’re thrilled to announce that Formosa Pharmaceuticals, Inc. has proudly received the prestigious Bronze Award 🏆 at the 2024 National Pharmaceutical Technology and Research Development Awards (NPRDA) sponsored by Taiwan FDA and Taiwan Industrial Development Administration! Heartfelt thanks to our dedicated team and to our colleagues, suppliers, partners, and all stakeholders for their invaluable support in making this achievement possible. 🔆 #APP13007 #ClobetasolBid #TFDA #NPRDA

✨ Formosa Pharmaceuticals, Inc. is thrilled to announce that our breakthrough case study, *"Improving Aerosol Delivery: Nanosuspension and Mesh Technology,"* led by Dr. YuChi Chen, our Director of Nanotechnology Development, has been published in the latest *ONdrugDelivery* Issue No. 167! A huge thanks to our partners at HCmed Innovations Co., Ltd. for collaborating with us to demonstrate how APNT nanoparticle technology enables efficient suspension delivery using the advanced AdheResp smart breath-actuated mesh nebulizer. This publication marks an exciting milestone in aerosol delivery innovation! ✨ Learn More - https://shorturl.at/HITPj #APNT #AdheResp #ONdrugDelivery #Nanosuspension

The Medical and Pharmaceutical Industry Technology and Development Center (PIDTC) hosted a seminar where Formosa Pharmaceuticals, Inc. had the privilege to showcase their APNT® nanoparticle formulation technology. Dr. YuChi Chen, the Director of Formosa Pharmaceuticals' Nanotechnology Division, delved into the advantages of nanoparticle formulation for enhancing the development of poorly water-soluble drugs. The success story of APP13007 served as a compelling example during the presentation. To explore further details about the APNT® nanoparticle formulation technology, visit: [Link to learn more](https://shorturl.at/1bRpd). 感謝財團法人醫藥工業技術發展中心邀請台新藥Formosa Pharmaceuticals, Inc.於經濟部產發署主辦的新製程技術推廣研討會分享APNT®奈米微粒製劑技術，在台新藥奈米技術處處長陳佑汲博士YuChi Chen搭配成功實例APP13007，深入淺出說明奈米化製劑技術對水溶性不佳的藥物開發上帶來的助益。 了解更多關於APNT®奈米微粒製劑技術：https://shorturl.at/z3oOm #APNT #Nanoparticle #FormulationTechnology #APP13007

We extend our heartfelt congratulations to our partners Grand Pharmaceutical Group Limited for the successful and efficient completion of their Phase 3 study (CPN-303) of APP13007 in Chinese patients for treating inflammation and pain following cataract surgery. We are pleased to see that their trial results align with the observations from our U.S. studies. We look forward to continued collaboration with Grand Pharma as they move toward the commercial launch in China. https://shorturl.at/6XmVE https://shorturl.at/V4ldV #ClobetasolBid #Phase3TopLine #OcularSurgery #CataractSurgery #AsianPopulation

This just in! Exciting news from Formosa Pharmaceuticals, Inc. and DÁVI - Farmacêutica as they announce a groundbreaking Licensing Agreement for APP13007 in the Portuguese Market. This strategic partnership signifies a significant milestone as it marks the companies' debut in the European market 🌍 . The collaboration not only paves the way for expansion in Portugal but also sets the stage for growth in other European territories. 🚀 Learn More: https://shorturl.at/kL0O8 https://shorturl.at/71PoU #Clobetasolbid #APP13007 #APNT #OcularSurgery #Cataract

Formosa Pharmaceuticals, Inc. successfully participated in CPhI 2024 Milan! A heartfelt thanks to our partners and friends for connecting with us at CPhI! 🌈 🍕 🥂 🌟 Special thanks to the MSD team at Formosa Laboratories, Inc. for all the support they have provided us! #FormosaPharma #FormosaLab #CPhI2024Milan #APP13007 #ClobetasolBID #ADCBiosimilar

Exciting News: 🚀 The Next Generation Ophthalmic Steroid Is Now Available in the US! 🚀 Thrilled to announce the commercial U.S. launch of clobetasol propionate ophthalmic suspension 0.05% (APP13007) developed by Formosa Pharmaceuticals, Inc. This highly anticipated development brings a formidable therapy to ocular surgery patients in the U.S. in partnership with Eyenovia, Inc. #ClobetasolBID #APP13007 #USLaunch

✨ We are excited to share that Formosa Pharmaceuticals, Inc. has been honored with the esteemed Gold Medal 🏆 for the Go-Global Award 🌏 at the 2024 Taipei Biotech Awards! We express our sincere appreciation to our committed team members and the continuous support from our shareholders, suppliers, partners, and all stakeholders. ✨ Learn more: https://shorturl.at/sulJF